HilleVax, Inc.
hillevax.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2025 10-Q, filed Aug 6, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Nov 14, 2025.
10-Q for Q2 FY2025, filed Aug 6, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops norovirus vaccine candidates intended to prevent illness in infants and other patient groups.
10-K for FY2024, filed Mar 28, 2025We are a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Our initial program, HIL-214…View ↗
In January 2024 we in-licensed rights to HIL-216, a hexavalent VLP vaccine candidate for norovirus that includes six common norovirus…View ↗
The burden of norovirus falls disproportionately on young children and older adults. Incidence of norovirus is highest among young…View ↗
How Did They Make Money?
No revenue was reported.
10-K for FY2024, filed Mar 28, 2025
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2025, filed Aug 6, 2025
−$5.3MView ↗
- ▼ −87% (Loss)
- vs −$40.7M in Q2 FY2024
-
Sep 17, 2025
XOMA Royalty completed its acquisition of HilleVax
HilleVax became a wholly owned subsidiary; stockholders’ shares converted into the right to receive $1.95 in cash per share plus a contingent value right.
Sources
8-K, filed Sep 17, 2025
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on August 18, 2025, Parent and Merger Sub…View ↗
-
Aug 4, 2025
HilleVax agreed to be acquired by XOMA Royalty
The offer provided $1.95 in cash per share plus a contingent value right tied to excess cash, lease savings and possible proceeds from remaining vaccine programs.
Sources
8-K, filed Aug 4, 2025
On August 4, 2025, HilleVax, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with XOMA Royalty…View ↗
Who Did They Compete With?
Competes with BioNTech, CSL Bering, GlaxoSmithKline, Merck, Moderna, Pfizer, Sanofi, Takeda, China National Biotec, Chongqing Zhifei Biological, Icon Genetics, and Vaxart
10-K for FY2024, filed Mar 28, 2025Our industry is characterized by rapidly advancing technologies, intense competition, and strong emphasis on proprietary products.…View ↗
Loading...
